Platelet Rich Plasma (PRP) Injections For Knee Osteoarthritis

Clinical Results Of Platelet Rich Plasma (PRP) Injections For Knee Osteoarthritis (KOA), Our Experience At Midterm Follow Up

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04852380

Enrollment

153

Registered

2021-04-21

Start date

2018-01-01

Completion date

2021-04-01

Last updated

2021-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis

Keywords

knee osteoarthritis (KOA); Platelet-rich plasma (PRP);

Brief summary

It was conducted a prospective study with a series of 153 patients treated with PRP injections in patient affected by knee osteoarthritis. One independent observer performed clinical and functional evaluations at T0 (recruitment), T1 (one month after the injection), T2 (three months after the last injection) and T3 (six months after the last injection). The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), the Knee Score Society (KSS) score and the Visual Analogue Scale (VAS) were evaluated and recorded for each patient at each follow up.

Interventions

PROCEDUREPRP injections

The 5 mL PRP concentrate was injected every week for three times, starting from recruitment. The patient was placed supine whit a knee flexion of 90°.All the procedures were carried out in an aseptic condition, injected in the knee soft spot through an anterior approach, using a 21-gauge needle.

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

40 Years to 81 Years

Healthy volunteers

Inclusion criteria

* Age between 40 and 81; * Body mass index (BMI) between 21.5 and 29.3; * Chronic history (for at least 4 months) of knee joint pain; * Radiographically documented knee osteoarthritis of grades 1 to 3 (Kellgren-Lawrence (K-L) radiographic classification scale)

Exclusion criteria

* Radiographically severe documented knee osteoarthritis of grade 4 (K-L radiographic classification scale); * Previous femur and tibia fractures; * Knee previous surgical treatment (e.g., arthroscopy); * Hyaluronic acid infiltration within the previous six months; * Hemoglobin levels \<10 g/dL; * History of oncohematological disease, infections, or immunodepression

Design outcomes

Primary

Measure	Time frame	Description
Change in Visual Analogic Scale	Day 0; Month 1; Month 3; Month 6 (after the injection)	The knee pain was quantified using the Visual Analogic Scale ranging from 0 (no pain) to 10 (worst imaginable pain).

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026